Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia, Open Label, Single Ascending Dose Study to Assess the Safety and Tolerability of KSI 301 in Patients with Diabetic Macular Oedema

Trial Profile

A Phase Ia, Open Label, Single Ascending Dose Study to Assess the Safety and Tolerability of KSI 301 in Patients with Diabetic Macular Oedema

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KSI 301 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; First in man
  • Sponsors Kodiak Sciences
  • Most Recent Events

    • 14 Aug 2019 According to a Kodiak Sciences media release, data presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting highlighted the final 12-week results of the Phase 1a clinical study of KSI-301 with sustained responses observed after a single dose of KSI-301, measured as improvement from baseline in vision, retinal anatomy, or both.
    • 25 Apr 2019 According to a Kodiak Sciences media release, the data from this study will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting.
    • 28 Mar 2019 According to a Kodiak Sciences media release, the data from this study were presented at the Angiogenesis, Exudation, and Degeneration 2019 medical meeting on February 9, 2019.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top